Company / Free Cash Flow
Syndax Pharmaceuticals Inc Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$323.2M
FY2025
5-year range
-$323.2M / -$50.7M
FY2021-FY2025
Trend
-17.6%
vs FY2024
Sector context
#172 of 194
Health Care
What the data says
Syndax Pharmaceuticals Inc's free cash flow of -$323M is lower than 89% of companies in the Health Care sector (FY2025). Free Cash Flow has declined for 4 consecutive years, from -$51M in FY2021 to -$323M in FY2025.
Based on SEC 10-K filings.
-$323M in FY2025.
Declined from -$161M to -$323M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 194This company -$323.2M Sector average $470.6M
▼
-168.7% below sector average
Key checks
Key Insights
- Syndax Pharmaceuticals Inc's free cash flow has declined for 4 consecutive years.
- In FY2025, free cash flow decreased 17.6% year-over-year.
- Ranks #172 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$323.2M | -17.6% |
| FY2024 | -$274.9M | -71.2% |
| FY2023 | -$160.6M | -20.1% |
| FY2022 | -$133.7M | -163.4% |
| FY2021 | -$50.7M | +26.2% |
| FY2020 | -$68.7M | -44.8% |
| FY2019 | -$47.5M | -34.0% |
| FY2018 | -$35.4M | -1329.9% |
| FY2017 | -$2.5M | +82.8% |
| FY2016 | -$14.4M | -481.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026